Europace (2007) 9, 707–710 doi:10.1093/europace/eum174
EDITORIAL
Asymptomatic Brugada syndrome: a cardiac ticking time-bomb? Sami Viskin* and Ori Rogowski Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Weizman 6, Tel Aviv 64239, Israel Online publish-ahead-of-print 22 August 2007
This editorial refers to ‘Role of programmed ventricular stimulation in patients with Brugada syndrome—a metaanalysis of worldwide published data’ by M. Paul et al., doi:10.1093/eurheartj/ehm1161
The opinions expressed in this article are not necessarily those of the Editors of Europace, the European Heart Rhythm Association or the European Society of Cardiology1 * Corresponding author. Tel: þ972 524266859; fax: þ972 36974416. E-mail address:
[email protected]
How can we explain the higher inducibility rate reported in the Brugada Series? One possible explanation is that patients in the Brugada Series have a worse disease and are therefore more inducible during EPS. The second possibility is that Brugada et al. achieve higher inducibility rates by using more aggressive EPS protocols. However, in the data compiled by Paul, the difference in inducibility cannot be credited to different patient characteristics or EPS protocols.1
Patient characteristics The two patient characteristics consistently associated with higher inducibility rates (and worse prognosis) are ‘male gender’3,5,7 and ‘presence of coved ST segment elevation in the resting electrocardiogram (ECG)’ (as opposed to its appearance after challenge with a sodium channel blocker).3,5,7 However, according to Paul, the percentage of males included in the Brugada Series and in the other studies is similar.1 The same is true for the percentage of patients with spontaneous coved-type ST-elevation.1 Thus the higher inducibility rates achieved in the Brugada Series cannot be attributed to easily identifiable patient characteristics.
Electrophysiologic studies protocols Brugada et al.3 stimulate only from the right ventricular apex (RVA), whereas other authors attempted to induce VF both from the RVA and the right ventricular outflow tract (RVOT).1 Even if one assumes that both sites are equally arrhythmogenic, simply by sequentially stimulating from two sites one would double the odds for inducing VF. In fact, two lines of evidence suggest that the RVOT is more
& The European Society of Cardiology 2007. All rights reserved. For permissions, please e-mail:
[email protected]
Downloaded from by guest on April 25, 2016
‘You have a ticking time-bomb in your body’ is an expression too commonly used by cardiovascular surgeons when counseling patients with asymptomatic aortic aneurysm. Such patients find it difficult to cope with their ‘ticking-bomb’ dilemma—which sooner or later may blow-out their aorta— and often opt for invasive therapy before the ‘risk-vs.benefits’ section of the discussion is over. Based on the growing number of patients undergoing cardioverter defibrillator (ICD) implantation because of ‘asymptomatic Brugada syndrome with inducible ventricular fibrillation (VF),’ it appears that many cardiologists have adopted a ticking-bomb approach. Such aggressive approach was driven by studies by Brugada et al.2–4 convincingly showing (i) that a high percentage of asymptomatic patients with Brugada syndrome develop spontaneous VF within 3 years of diagnosis and (ii) that electrophysiologic studies (EPS) identify patients at risk for this potentially lethal outcome.2–4 More recent studies, however, do not confirm these observations.5,6 In this issue of the European Heart Journal, Paul et al.1 report a meta-analysis of Brugada syndrome that will force clinicians to pause and reevaluate the evidence supporting current practices. Paul et al.1 carefully reviewed the literature and painstakingly contacted the authors of every study reporting on EPS in Brugada syndrome. They were able to compare data from .400 patients included in the ‘Brugada Series‘ (which is the largest data-base reported by Brugada et al.),3 with data from .700 patients included in 15 different studies, referred to here as ‘the other studies.’1 The main findings of Paul’s analysis1 are: (i) patients included in the Brugada Series have higher
inducibility rates during EPS than patients included in all ‘the other studies‘ (Figure 1); (ii) the high rate of spontaneous arrhythmic events reported in the Brugada Series was not observed in the other studies, explaining why other studies failed to reproduce the high positive predictive value for EPS (Figure 2).
708
Editorial
This is important because the odds of inducing VF increase as the coupling interval is shortened ,200 ms.15 Thus, the higher inducibility rate in the Brugada Series cannot be ascribed to more aggressive EPS protocols since the protocol used by Brugada is definitively less aggressive than protocols used by others.
The ‘founders’ effect’
Figure 1 Inducibility of patients with Brugada syndrome according to their clinical presentation. Based on data collected by Paul et al.1 ‘Brugada series’ refers to the latest report by Brugada et al.3 The term ‘other studies’ refers to publications summarized by Paul et al.1 in their Table 2.
Initial descriptions of hypertrophic cardiomyopathy from tertiary centres portrayed a very grim prognosis.16 As newer community-based studies appeared, a more balanced and less ominous picture was recognized.16 We may now be observing a similar phenomenon in Brugada syndrome. As shown in Figure 1 of Paul’s paper,1 the percentage of asymptomatic patients who went on to develop spontaneous VF during follow-up decreased in successive reports of the Brugada Series (from 27% in their initial publication2 to 8% in their second report17 and to only 5% in their most recent publication3). Patients included in the first report2 also appeared in subsequent publications,3,17 and apparently contributed the majority of arrhythmic events.
Induction of ventricular fibrillation in asymptomatic patients: what does it mean?
arrhythmogenic. First, review of the studies8–14 reporting the contribution of each stimulating site to VF induction shows that 43 and 57% of VF episodes were induced from the RVA and from the RVOT, respectively. This difference is meaningful because, generally, only patients who are non-inducible from the RVA undergo RVOT stimulation. Secondly, in one study meticulously comparing pacing sites, VF was always induced from the RVOT but was induced from the RVA in only 12% of patients and was never induced from the left ventricle.13 Studies also differ in the minimal coupling interval of the extrastimuli, whereas Brugada et al.3,4 limit the coupling interval of the ventricular extrastimuli to 200 ms, others limit the coupling interval only by ventricular refractoriness.
Downloaded from by guest on April 25, 2016
Figure 2 Predictive value of electrophysiologic studies in asymptomatic patients with Brugada syndrome. Based on data collected by Paul et al.1 and data from a Japanese Registry (personal communication from W. Shimizu and S. Kamakura). ‘Brugada series’ and ‘other studies’ as in Figure 1. White bars and hatched bars represent partition of patients according to the results of the electrophysiologic studies (EPS); black bars denote the incidence of spontaneous ventricular fibrillation during follow-up. Inducibility rates are not those shown in Figure 1 because not all the patients appearing in that figure also appear here (not all studies reporting EPS results also reported follow-up events).
The odds of inducing VF in patients with Brugada syndrome are highest for cardiac arrest survivors, intermediate for patients with syncope and lowest for asymptomatic patients.1,3,6,17 This association between the vulnerability to spontaneous and induced ventricular arrhythmias suggests that EPS is of diagnostic value.18 It does not necessarily mean that the prognostic value of EPS is robust enough for clinical-decision making. Two decades ago, debates similar to those now surrounding Brugada syndrome were held about the role of EPS in patients with heart disease.19 Animal data had shown that 40% of healthy dogs have inducible VF with double extrastimulation and that the inducibility rate increases to 100% when triple extrastimulation is performed from multiple ventricular sites.20 Thus, to establish the specificity of inducible ventricular arrhythmias, a few studies included patients considered to be at no risk for spontaneous arrhythmias as controls.21–25 It became evident that up to 6% of controls have inducible VF with protocols using up to three extrastimuli (Table 1). This 6% figure, however, underestimates the risk for ‘false positive’ (i.e. accidental) induction of VF because, to avoid the need for DC shock defibrillation in controls, the EPS protocol was prematurely terminated (when inductions of non-sustained polymorphic VT occurred) in 45% of controls (Table 1). Of note, the odds for inducing VF raise as the number of extrastimuli increases and their coupling interval is shortened. Unfortunately, this holds true both for ‘false positive’ VF inductions (i.e. the accidental provocation of VF in controls)15 and for ‘true positive’ VF inductions (i.e. in patients prone to develop spontaneous VF).26 Consequently, understanding the clinical significance of VF induction in asymptomatic patients, especially when the arrhythmia is induced with triple extrastimulation and short coupling intervals, is problematic. Figure 2 shows the predictive value of EPS in patients with asymptomatic Brugada syndrome. The figure includes data for 263 patients included in the Brugada Series3 and 441
Editorial
709
Table 1 Electrophysiologic studies that included patients at low risk for spontaneous arrhythmias as controls to evaluate the specificity of programmed stimulation Reference
Brugada et al.a22 Morady et al.24 Buxton et al.23 Stevenson et al.25 Belhassen et al.21
Controls
35 NHD + SVT 52 NHD ¼ 16 28 NHD 32 NHD þ SVT 30 NHD þ VE
Pacing sites, BCL; output
RVA, 1 BCL; 2DT RVAc, 2 BCL; 5 mA RVA, 2 BCL; 2DT RVA, 3 BCL; 2DT RVA þ RVOTe, 3 BCL; 3 mA
Inducible NSPVT
Inducible VF
Double VES
Triple VES
Double VES
Triple VES
15% 6% NA 38% 10%
33% 35% 34% 41% ND
3% 2% 4% NA 7%
6%b 4% 6%d 4%b 6%b ND
In all these studies, the coupling interval of the extrastimuli was shortened until ventricular refractoriness was reached. Controls: NHD þ SVT, NHD þ VE ¼ Patients with no heart disease evaluated for supraventricular tachycardia (SVT) or for ventricular extrasystoles (VE). RVA, RVOT ¼ right ventricular apex and outflow tract. a Data for NSVT inducibility available for 52 patients considered to be at low risk for arrhythmias, including 35 patients with no heart disease.34 b In these studies, induction of NSPVT, of 6 beats or more, led to premature ending of the pacing protocol. c In this study, 14 patients also underwent left ventricular stimulation. d 6% of patients with no heart disease had inducible VF with double extrastimulation. e In this study, repetition of extrastimulation at the shortest coupling interval capturing the ventricle was performed 10 times. 2DT, pacing output was twice the diastolic pacing threshold; BCL, basic cycle lengths; VF, ventricular fibrillation. NSPVT, non-sustained polymorphic ventricular tachycardia; Double VES and triple VES, double and triple ventricular extrastimulation, respectively; NA, data not available; ND, not done.
Conclusion, limitations and clinical implications The meta-analysis by Paul et al.1 shows that patients in the Brugada Series have high inducibility rate at EPS and high risk for subsequent spontaneous arrhythmias. Neither of these findings was substantiated by the other studies. As discussed above, it appears that the first patients recognized by Brugada et al. contributed an extraordinary number of spontaneous arrhythmic events, which in turn translated into better predictive accuracy for the EPS. Reaching conclusions based on meta-analysis is risky. If one employs the meta-analysis approach, the pooled random effect of the vent rate in the other studies is 5.6% (95% confidence intervals 3.2–9.6%) compared to point estimation of 12% (95% confidence intervals 6.8–20.5%) in the ‘Brugada series’. The fact that the confidence intervals overlap suggests that the ‘true risk’ is somewhere in between. The critical question is what to do until definitive data with longer follow-up periods are available. Prophylactic ICD implantation in Brugada syndrome is accompanied by
high rates of complications.27,28 Infection after ICD replacements, as well as inappropriate ICD shocks (due to T-wave over-sensing, atrial arrhythmias, or lead fractures) are common in young patients.27,28 A recent European study reported serious complications in 28% of patients undergoing ICD implantation, whereas the odds for life-saving ICD therapy were only 1% per year for initially asymptomatic patients. Thus, it is morally justifiable to consider alternative approaches even if they are not entirely risk-free. Patients with Brugada syndrome may be ideal candidates for the extra-cardiac subcutaneous ICD (S-ICD) because they need only shock therapy. Patients should know that it may be in their best interest not to undergo ICD implantation now, but wait for the S-ICD, which may soon be available. In the meantime, patients and their relatives should master cardiopulmonary resuscitation and should learn about the advances in home-monitoring of arrhythmias and external automatic defibrillators. Finally, patients should be given the option of prophylactic drug therapy. Betablockers are the first-line of therapy for low- and mediumrisk patients with congenital long QT syndrome and many enjoy years of safety with beta-blockers as their only therapy. The irony is that most of them would have undergone ICD implantation if the device had been available when the long-QT syndrome was described (as happened for Brugada syndrome). Quinidine appears to be a suitable therapy for this disease because of the following: (i) quinidine prevents phase-II reentry and VF in the wedge preparation of Antzelevitch;29 (ii) fully 7630–88%8 of patients who have inducible VF at baseline EPS are rendered noninducible by quinidine therapy; (iii) quinidine is effective for aborting VF-storms;31 (iv) limited clinical data (from work pioneered by Belhassen)32 suggests that quinidine prevents spontaneous arrhythmias in high-risk patients with Brugada syndrome.8,30
Acknowledgements We remain indebted to Dr M. Paul and Dr A. A. M. Wilde for allowing us access to the data meticulously collected for their meta-
Downloaded from by guest on April 25, 2016
patients from the other studies. The last group includes data carefully collected by Paul1 for 351 patients from 10 studies reporting EPS results and follow-up events, as well as data from 90 asymptomatic patients (including 52 patients with inducible VF) participating in a Japanese Registry that has not been published (data kindly provided by Drs Kamakura and Shimizu). There is universal agreement on the excellent negative predictive value of EPS (Figure 2). However, disagreement surrounds the positive predictive value of EPS. In the Brugada Series, 34% of asymptomatic patients had inducible VF and 12% of the latter developed spontaneous VF. These numbers are the basis for the recommending prophylactic ICD implantation when the EPS is positive. Yet, in the other studies only 9 (3.6%) of 254 asymptomatic patients with inducible VF developed spontaneous VF (with follow-up periods approaching 3 years in the larger studies). Information about the presence of spontaneous ‘coved-type’ ST-segment elevation was available for only 136 patients. For these patients, the risk for spontaneous VF—if the EPS was positive—was 5.1%.
710
Editorial
analysis.1 We thank Dr W. Shimizu and Dr S. Kamakura for allowing us to include data from the Japanese Registry. We thank Dr N. Hagiwara for providing follow-up data for patients included in the study by Ajiro et al.33
18.
Conflicts of interest: none declared.
19.
References 20.
21.
22.
23.
24.
25.
26.
27.
28.
29. 30.
31.
32.
33.
34.
Downloaded from by guest on April 25, 2016
1. Paul M, Gerss J, Schulze-Bahr E, Wichter T, Vahlhaus C, Wilde AAM, Breithardt G, Eckardt L. Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. Eur Heart J 2007 doi:10.1093/eurheartj/ehm116. 2. Brugada J, Brugada P. Right bundle branch block and ST segment elevation in leads V1 through V3. A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97: 457–60. 3. Brugada P, Brugada R, Rivero M, Geelen P, Brugada J. Natural history of Brugada syndrome: The prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol 2003;14:455–7. 4. Brugada P, Geelen P, Brugada R, Mont L, Brugada J. Prognostic value of electrophysiologic investigations in Brugada syndrome. J Cardiovasc Electrophysiol 2001;12:1004–7. 5. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002;105:1342–7. 6. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol 2006;17:577–83. 7. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm 2005;2:429–40. 8. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110:1731–7. 9. Eckardt L, Kirchhof P, Schulze-Bahr E, Rolf S, Ribbing M, Loh P et al. Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. Eur Heart J 2002;23:1394–401. 10. Furushima H, Chinushi M, Hirono T, Sugiura H, Watanabe H, Komura S et al. Relationship between dominant prolongation of the filtered QRS duration in the right precordial leads and clinical characteristics in Brugada syndrome. J Cardiovasc Electrophysiol 2005;16:1311–7. 11. Gasparini M, Priori SG, Mantica M, Coltorti F, Napolitano C, Galimberti P et al. Programmed electrical stimulation in Brugada syndrome: how reproducible are the results? J Cardiovasc Electrophysiol 2002;13:880–7. 12. Kanda M, Shimizu W, Matsuo K, Nagaya N, Taguchi A, Suyama K et al. Electrophysiologic characteristics and implications of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. J Am Coll Cardiol 2002;39:1799–805. 13. Morita H, Fukushima-Kusano K, Nagase S, Takenaka-Morita S, Nishii N, Kakishita M et al. Site-Specific Arrhythmogenesis in Patients with Brugada Syndrome. Journal of Cardiovascular Electrophysiology 2003; 14:373–9. 14. Park DW, Nam GB, Rhee KS, Han GH, Choi KJ, Kim YH. Clinical characteristics of Brugada syndrome in a Korean population. Circ J 2003;67:934–9. 15. Morady F, DiCarlo L, Baerman J, de Buitleir M. Comparison of coupling intervals that induce clinical and nonclinical forms of ventricular tachycardia during programmed stimulation. Am J Cardiol 1986;57:1269–73. 16. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989;320:749–55. 17. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the
electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002; 105:73–8. Viskin S. Inducible ventricular fibrillation in the Brugada syndrome: diagnostic and prognostic implications. J Cardiovasc Electrophysiol 2003;14: 458–60. Wellens HJJ, Brugada P, Stevenson WG. Programmed ventricular stimulation of the heart in patients with life-threatening ventricular arrhythmias: what is the significance of induced arrhythmias and what is the correct stimulation protocol? Circulation 1985;72:1–7. Wetstein L, Michelson EL, Simson MB, Moore EN, Harken AH. Initiation of ventricular tachyarrhythmia with programmed stimulation: sensitivity and specificity in an experimental canine model. Surgery 1982;92: 206–11. Belhassen B, Shapira I, Sheps D, Laniado S. Programmed ventricular stimulation using up to two extrastimuli and repetition of double extrastimulation for induction of ventricular tachycardia: a new highly sensitive and specific protocol. Am J Cardiol 1990;65:615–22. Brugada P, Green M, Abdollah H, Wellens HJJ. Significance of ventricular arrhythmias initiated by programmed ventricular stimulation: the importance of the type of ventricular arrhythmia induced and the number of premature stimuli required. Circulation 1984;69:87–92. Buxton AE, Waxman HL, Marchlinski FE, Untereker WJ, Waspe LE, Josephson ME. Role of triple extrastimuli during electrophysiologic study of patients with documented sustained ventricular tachyarrhythmias. Circulation 1984;69:532–40. Morady F, Shapiro W, Shen E, Sung RJ, Scheinman MM. Programmed ventricular stimulation in patients without spontaneous ventricular tachycardia. Am Heart J 1984;107:875–82. Stevenson WG, Brugada P, Waldecker B, Zehender M, Wellens HJ. Can potentially significant polymorphic ventricular arrhythmias initiated by programmed stimulation be distinguished from those that are nonspecific? Am Heart J 1986;111:1073–80. Eckardt L, Probst V, Smits JP, Bahr ES, Wolpert C, Schimpf R et al. Longterm prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 2005;111:257–63. Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gerard F et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006;114: 2317–24. Sarkozy A, Boussy T, Kourgiannides G, Chierchia GB, Richter S, De Potter T et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007;28:334–44. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12:268–72. Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43:1853–60. Marquez MF, Salica G, Hermosillo AG, Pastelin G, Cardenas M. Drug therapy in Brugada syndrome. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:409–17. Belhassen B, Shapira I, Shoshani D, Paredes A, Miller H, Laniado S. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents. Circulation 1987;75:809–16. Ajiro Y, Hagiwara N, Kasanuki H. Assessment of markers for identifying patients at risk for life-threatening arrhythmic events in Brugada syndrome. J Cardiovasc Electrophysiol 2005;16:45–51. Brugada P, Abdollah H, Heddle B, Wellens HJ. Results of a ventricular stimulation protocol using a maximum of 4 premature stimuli in patients without documented or suspected ventricular arrhythmias. Am J Cardiol 1983;52:1214–8.
